Primaura Therapeutics today announced its launch with a mission to develop next-generation genomic medicines that precisely restore physiological protein expression.The company's proprietary platform, BOOST 2.0, focuses on modulating translation through targeted editing of the Kozak sequence, a key regulator of translation initiation. By fine-tuning endogenous protein production rather than replacing genes or introducing exogenous DNA, Primaura aims to address the underlying causes of dosage-sensitive genetic disorders."Our vision is to transform the way protein dosage disorders are treated by restoring balance at the source of protein expression," said the Primaura Therapeutics founding team.The company is currently advancing its platform technology while building strategic collaborations within the scientific and biotechnology communities.Further updates on scientific progress, partnerships and future milestones will be shared as the platform continues to evolve.
